“With the lifting of the clinical hold, we are thrilled to reengage with doctors and hospitals to work towards developing DM199 as a significant advance for the treatment of ischemic stroke patients,” commented Rick Pauls, DiaMedica’s Chief Executive Officer. “We look forward to keeping you updated on the progress of our trial.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DMAC:
- DMAC Earnings this Week: How Will it Perform?
- DiaMedica Therapeutics files to sell 11.01M shares of common stock for holders
- Biotech Alert: Searches spiking for these stocks today
- DiaMedica Therapeutics director and exec each buys $150K in common stock
- Oppenheimer upgrades DiaMedica to Outperform following clinical hold lift
